Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720801 | 0.87 | HRH3 (0.47) | DRD3DRD2HRH3KCNJ1KCNH2 | |
| SCHEMBL1483704 | 0.81 | RAB9A (0.53) | DRD3DRD2HRH3KCNJ1KCNH2 | |
| SCHEMBL7253895 | 0.75 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL2514685 | 0.75 | HRH3 (0.52) | DRD3DRD2HRH3MEN1 | |
| SCHEMBL4233204 | 0.74 | DRD2 (0.70) | DRD3DRD2HRH3KCNJ1KCNH2 | |
| SCHEMBL14722630 | 0.70 | ACHE (0.41) | DRD3KCNH2RAB9A | |
| SCHEMBL14720404 | 0.70 | ALDH1A1 (0.46) | — | |
| SCHEMBL4240820 | 0.69 | DRD2 (0.64) | DRD3DRD2HRH3HRH2HRH1 | |
| SCHEMBL3348927 | 0.69 | DRD2 (1.00) | DRD3DRD2HRH3HRH1 | |
| SCHEMBL16256936 | 0.69 | KCNA5 (0.59) | DRD3DRD2HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |